CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Alnylam Partner Regeneron's CIDEBsiRNA Cuts Liver Fat by Up to 80% in Early Trial

By Public Technologies
  • Alnylam Pharmaceuticals announced first-in-human results showing its Regeneron-partnered CIDEBsiRNA rapidly normalized liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
  • A single injection also improved liver injury markers, with effects sustained through 36 weeks in the ongoing Phase 1/2 trial.
  • Results were presented at AASLD's The Liver Meeting 2026 and published simultaneously in The New England Journal of Medicine.
  • Regeneron leads development and holds exclusive commercialization rights for the investigational treatment.
  • The partnership entitles Alnylam to development milestones and tiered, double-digit royalties up to 20%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101000BIZWIRE_USPR_____20261110_BW694883) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk